生化基因(BIIB)
icon
搜索文档
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
ZACKS· 2024-07-25 23:07
Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on August 1, 2024, might help the stock move higher if these key numbers are better than expect ...
Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm
GlobeNewswire News Room· 2024-07-22 23:54
NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=91392&from=3 CLASS PERIOD: February 3, 2022 to Februar ...
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB
GlobeNewswire News Room· 2024-07-19 21:31
SAN DIEGO, July 19, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024, inclusive (the “Class Period”), have until this upcoming Monday, July 22, 2024 to seek appointment as lead plaintiff in the Biogen class action lawsuit. Captioned Gray v. Biogen Inc., No. 24-cv-01444 (D. Colo.), the Biogen class action lawsuit charges Biogen and certain of Biogen’s top current and former ...
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
ZACKS· 2024-07-17 22:51
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?D ...
The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
Prnewswire· 2024-07-17 17:45
NEW YORK, July 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB).Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=90890&from=4CLASS PERIOD: February 3, 2022 to February 13, 20 ...
INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB
GlobeNewswire News Room· 2024-07-16 17:45
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024, inclusive (the “Class Period”), have until Monday, July 22, 2024 to seek appointment as lead plaintiff in the Biogen class action lawsuit. Captioned Gray v. Biogen Inc., No. 24-cv-01444 (D. Colo.), the Biogen class action lawsuit charges Biogen and certain of Biogen’s top current and former executives wit ...
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
Newsfilter· 2024-07-16 17:10
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing This new financing will support broad late-stage clinical development program for visugromab, CatalYm's lead product candidate in cancer immunotherapy.After a first investment as co-lead investor in CatalYm's €50 million series C financing (November 2022), Jeito's new participation in this oversubscribed round, alongside new international biopharma investors, confirms CatalYm's strong progress and pot ...
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
GlobeNewswire News Room· 2024-07-16 17:10
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing This new financing will support broad late-stage clinical development program for visugromab, CatalYm’s lead product candidate in cancer immunotherapy.After a first investment as co-lead investor in CatalYm’s €50 million series C financing (November 2022), Jeito’s new participation in this oversubscribed round, alongside new international biopharma investors, confirms CatalYm’s strong progress and pot ...
Biogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB
Prnewswire· 2024-07-16 16:00
LOS ANGELES, July 16, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ:BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff ...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit – BIIB
GlobeNewswire News Room· 2024-07-15 23:21
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=90500&from=3 CLASS PERIOD: February 3, 2022 to Februar ...